Dev Prasad
Stock Analyst at LUCID CAPITAL MARKETS
(2.97)
# 1,370
Out of 5,135 analysts
6
Total ratings
60%
Success rate
73.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma | Downgrades: Neutral | $11 → $1 | $0.98 | +1.73% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiates: Buy | $4 | $0.29 | +1,274.10% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $5 | $3.89 | +28.53% | 1 | Jun 17, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $24 | $15.07 | +59.26% | 1 | Dec 17, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $6 | $2.29 | +162.01% | 1 | Dec 17, 2024 | |
| CALC CalciMedica | Initiates: Buy | $13 | $0.61 | +2,021.76% | 1 | Dec 17, 2024 |
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: $11 → $1
Current: $0.98
Upside: +1.73%
Cue Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $4
Current: $0.29
Upside: +1,274.10%
Opus Genetics
Jun 17, 2025
Initiates: Buy
Price Target: $5
Current: $3.89
Upside: +28.53%
Avalo Therapeutics
Dec 17, 2024
Initiates: Buy
Price Target: $24
Current: $15.07
Upside: +59.26%
iBio, Inc.
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.29
Upside: +162.01%
CalciMedica
Dec 17, 2024
Initiates: Buy
Price Target: $13
Current: $0.61
Upside: +2,021.76%